Biblio
Advancements and future trends of immunotherapy in light-chain amyloidosis. Crit Rev Oncol Hematol. 2023:103917.
. The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma. Bone Marrow Transplant. 2023.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.
Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. Med Oncol. 2022;40(1):36.
. Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. Acta Haematol. 2016;136(4):244-255.
. Outcome of Fludarabine Based Conditioning in High Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single Center Study from Pakistan. Biol Blood Marrow Transplant. 2019.
Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. Clin Case Rep. 2015;3(9):728-30.
. Progress in Research: Daratumumab Improves Treatment Outcomes of Patients with AL Amyloidosis. Crit Rev Oncol Hematol. 2021:103435.
. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review. Biol Blood Marrow Transplant. 2019.
Revisiting role of vaccinations in donors, transplant recipients, immunocompromised hosts, travelers and household contacts of stem cell transplant recipients. Biol Blood Marrow Transplant. 2019.
Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities. JCO Oncol Pract. 2024:OP2300672.
. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors Before and After Allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Single agent Cyclosporine for Graft versus host disease prophylaxis in patients with acquired Aplastic Anemia receiving fludarabine based conditioning. Biol Blood Marrow Transplant. 2020.